Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of heparin and fondaparinux in critically ill patients with severe sepsis
ACTRN12606000285550Phase 4Not yet recruiting
- Sponsor
- Dr M Robertson
- Start
- Jul 2006
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of heparin and fondaparinux in sepsis, sponsored by Dr M Robertson. Primary endpoint: Bioavailability of heparin and fondaparinux via factor Xa inhibition. Planned start Jul 2006; status: not yet recruiting.
02
Drugs
heparinfondaparinux
03
Conditions
sepsis
Beyond the preview
Go deeper on ACTRN12606000285550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000285550.